These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9354931)

  • 21. Suppression of heat-induced HSF activation by CDDP in human glioblastoma cells.
    Matsumoto H; Hayashi S; Shioura H; Ohtsubo T; Kitai R; Ohnishi K; Hayashi N; Ohnishi T; Kano E
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):915-20. PubMed ID: 9652857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells.
    Di Blasi P; Bernareggi A; Beggiolin G; Piazzoni L; Menta E; Formento ML
    Anticancer Res; 1998; 18(4C):3113-7. PubMed ID: 9713519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
    Teicher BA; Pfeffer MR; Alvarez Sotomayor E; Herman TS
    Int J Hyperthermia; 1991; 7(5):773-84. PubMed ID: 1834752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of cis-diamminedichloroplatinum(II) resistance: a review.
    Timmer-Bosscha H; Mulder NH; de Vries EG
    Br J Cancer; 1992 Aug; 66(2):227-38. PubMed ID: 1503895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell.
    Mese H; Sasaki A; Alcalde RE; Nakayama S; Matsumura T
    Chemotherapy; 1998; 44(6):414-20. PubMed ID: 9755302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitization to cisplatin action by step-down heating in cDDP-sensitive and -resistant cells.
    Hettinga JV; Lemstra W; De Vries EG; Konings AW; Kampinga HH
    Int J Cancer; 1995 May; 61(5):722-6. PubMed ID: 7768647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor.
    Nishita T
    Osaka City Med J; 1998 Jun; 44(1):73-83. PubMed ID: 9834620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
    Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
    Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.
    Nakamura T; Koizumi F; Kaneko N; Tamura T; Chiwaki F; Koh Y; Akutagawa S; Saijo N; Nishio K
    Jpn J Cancer Res; 2001 Jun; 92(6):597-602. PubMed ID: 11429046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
    Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive effects of cepharanthin in CDDP/hyperthermia combination therapy against transplantable human esophageal cancer in nude mice.
    Yano T; Nakatani K; Watanabe A; Sawada H; Yamada Y; Nakano H; Ohnishi T
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):525-8. PubMed ID: 8005810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
    Zhan M; Liu X
    Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
    Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
    Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
    Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
    Zhang MC; Hu CP; Chen Q
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of SESN1 reduces cisplatin and hyperthermia resistance through increasing reactive oxygen species (ROS) in human maxillary cancer cells.
    Narita N; Ito Y; Takabayashi T; Okamoto M; Imoto Y; Ogi K; Tokunaga T; Matsumoto H; Fujieda S
    Int J Hyperthermia; 2018 Dec; 35(1):269-278. PubMed ID: 30300027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
    Mizutani Y; Wu XX; Yoshida O; Shirasaka T; Bonavida B
    Oncol Rep; 1999; 6(5):979-82. PubMed ID: 10425290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
    Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
    Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.